Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The whole mmj market in Nevada is being delayed because of the State trying to set new pesticide testing standards. PZOO didn't do anything! Everyone including dispensaries, growers or testers are delayed. PZOO is still doing great!
Seriously! How many shares you have or want?
PZOO tests marijuana! Good for business!
NEVADANS, DISPENSARIES FACE LONGER WAIT FOR MEDICAL POT
Nevadans might not be able to buy marijuana in legal dispensaries until summer — or later — as a legal tangle continues over pesticide rules.
The delay means continued frustration for patients and lost money for businesses that once hoped to begin selling medical pot in January.
It could be months until workable pesticide limits are in place — and even longer before the first significant marijuana crops are ready.
“Nobody can start growing until it’s resolved,” said Shane Terry, CEO of NuVeda, a company that plans to open dispensaries and grow operations.
The problem centers on a Nevada regulation that says marijuana tested in state-licensed labs must meet the “most stringent acceptable standard for an approved pesticide chemical residue in any food item” under federal rules.
Read literally, that means marijuana can’t have any more residue than milk or meat, which are not treated with pesticides.
“If anybody uses a regulated pesticide on a plant, it’s going to fail, because the levels would be almost impossible to achieve,” said Savino Sguera, a lab director and member of a state advisory committee.
Before any marijuana can be sold in Nevada, it must be tested by a licensed lab for levels of cannabinoids, microbial contaminants, heavy metals and pesticide residue, among other things. The Independent Laboratory Advisory Committee is supposed to help set the standards labs will use.
During its April 1 meeting, committee members suggested testing marijuana with the pesticide limits used for plants such as lettuce or berries. But after consulting with the attorney general’s office, the state Division of Public and Behavioral Health said this week that would require changing a regulation, which it can’t do until after the Legislature adjourns June 1.
The lab advisory committee could vote on pesticide rules Thursday. But that move would largely be moot if the rules are unworkable, members said.
The delay affects the 9,000 Nevadans who already have patient cards, plus thousands more who might benefit from marijuana. Almost 6,500 cardholders are in Clark County, a number that grew by 65 percent over the past year.
“Patients right now are currently either growing their own, which is just a small minority, or they’re purchasing from these illegal dispensaries and delivery services,” said Jason Sturtsman, an advisory committee member who also is an owner of a North Las Vegas cultivation business.
Many people who want medical marijuana haven’t sought cards yet, because “they know there’s no dispensaries (where) they can walk in and get it,” said Dee Powers, founder of Karma Holistic Health Foundation.
So sick people continue taking prescription drugs that can have serious side effects, said Powers, whose foundation helps patients get marijuana cards.
Karma also encourages people to grow their own marijuana, Powers said.
Dispensaries can sell medicine grown by patient cardholders, but that supply would be limited and expensive, Sguera said. And it would have to be tested, too.
When the state gave provisional approval to marijuana businesses in November, people in industry and government said the first dispensaries could open in January.
Businesses have spent hundreds of thousands of dollars to design and build their operations. Some have started paying employees, including Euphoria Wellness, a dispensary that held a March 31 open house and ribbon cutting.
At that event, potential customers asked when the shop expected to open. Employees said they hoped it would be by the end of the following week.
20 cents would still put Pazoo's market cap at or below the average market cap of CANL. How's that for perspective of what this stock can do!
That's just the beginning! Wait 2...3...4...5 years from now!
Great job, Monkey13! Very accurate and factual!
Why? Their Outstanding Share count is too low for that! They are perfectly positioned right now.
I predict $.10 by this Summer
The only share count that effects the balance sheet and investors is the outstanding share count! You learn that in Investing 101.
Outstanding Shares:
450 Million
Company has NO plans for dilution in the near future
The A/S share count has no effect on investors or pps.
I agree. If it's one thing we can all agree on it's that the marijuana sector is only going to get bigger. Meaning PZOO is only going to get bigger. Remember this...Being ranked #1 will only benefit them exponentially as States work to pass more stringent testing laws. Companies will be going to PZOO to ensure they meet requirements. Smaller competitors will be pushed out of the market all together.
Short Term Catalysts:
1) Colorado facility opens within a month
2) Las Vegas facility opens within a month
3) Oregon facility opens in July
Translation:
Revenue + Revenue + Revenue = Huge Profits
Huge Profits = High PPS !!!!!!!
*Don't forget they have more aggressive expansion planned across multiple states. Also, they own the exclusive rights to use the technology of Steep Hill Labs (ranked the #1 marijuana tester). The have an O/S count of 450 million with no plans to dilute in the near future.
The owner said it the best when he stated PZOO is no longer a company in its "Developmental" Phase. We are in our "Growth" Phase! Very few MMJ companies can say that!
I agree. If "aggressive" expansion proceeds as they say, I can easily see this going $1.00+ in the next 1-2 years. This is a long play, not a trade imo! If they bring in just $15 million in profits and you apply an extremely conservative P/E of 12, the price already goes to
$.40. That should be attainable with the 3 locations. Most would use a P/E of 24 and CANL's P/E is even higher than that!!!
When you take into the increasing revenue stream, outstanding share count and P/E ratio, I believe the pps will be much, much higher than the
.05 - .10 people are hoping for! 1 to 2 years from now, people will wish they got in at .05 - 10. There are many stocks I like, but only a few like PAZOO that I am this confident in!
For the company's and investor's near future, this deal is way BIGGER than the opening of the Las Vegas facility. With 100% ownership of a facility in a legal state, Colorado will produce way more REVENUE/PROFITS than Las Vegas! BOOM!
True. Now they must be accountable which is great! Still, there is a huge difference between misleading investors and just having a change in plans. A change is allowed to achieve the same end result. They are a company in their infant stage so I would expect some glitches to come our way. Especially when you're dealing with government, partnerships and contractors. As long as they continue to be transparent and don't try to hide stuff as other companies do, I'll remain an investor and supporter!
Simple...they don't collect a real stream of revenue yet. They are opening 2 facilities in Las Vegas and Oregon in the next few months. Together, they should bring in millions of revenue! In addition to these 2, they already announced they plan on aggressively expanding to multiple other states. That's why!
This is 100% why the increase in Authorized Shares is an incredible and exciting thing! PZOO is a good on their word!!!
Pazoo Co-CEO David Cunic stated, "Our management team has become a well rounded group and we want to express our gratitude to all the support that we have received to date. This begins a new time for all Pazoo shareholders as we expect to experience a very aggressive period for expansion and growth."
Pazoo Co-CEO Antonio Del Hierro said, "We are basically set in Nevada and ready to ramp up operations in a big way. Oregon will be our launching pad for Harris Lee, LLC, with an aggressive expansion plan moving forward for the rest of the United States. I'm thrilled to be a part of something so grand."
Exactly!
The number of A/S share does Not effect the pps or investors! The O/S share count does and at this time that is not effected. This increase in A/S has to be done for expansion in the future as they plan to expand aggressively to multiple states. This is NOT a bad thing. It's a good thing because it shows the company is getting ready to hit the expansion thing hard. Another post used Amazon as an example. They have approx. 475,000,000 O/S, but 5,000,000,000 A/S! This is a good thing for the future of PZOO. I bet you they end up only using a few hundred million over the next few years, if that. The rest of the A/S just ensures they maintain the majority stake in the company.
Can anyone explain how CANL has a market cap of $100 million with revenue of only $1 million? If we use these metrics, PZOO will kill it!
Do you know why in an interview, they implied there was a possibility they wouldn't hit the 4/20 grand opening?
Haha! These types of threads get out of control sometimes. Hence...realistically. I was just hoping someone with knowledge of Biotechs would have good insight on the potential revenue projections, standard P/E ratio and estimates on how a potential pipeline validation could "realistically" effect INO's pps. Both in relation to approval of a Phase 3 study and then in relation to an FDA approval. That's what I meant.
HOW LONG DO WE EXPECT THE JUDICIAL REVIEW TO TAKE??? Does anyone really know or have experience with this?
Realistically...where do we see the pps going if 1) VGX-3100 officially announces its approval for a phase 3 study or 2) VGX-3100 gets approved. Assume no partnerships were garnered.
I thought news was coming out today
What realistic PPS do you think PZOO can reach by end of year?
Yes...Bill "momentarily" filed for judicial review, but who said he never filed the appropriate appeal with HC for the rejection letter? As far as I understand, we don't know that. They very well may have.
What happened to Everywhereman? I wonder what his opinion is lately.
They can't because it would violate security and quality control measures put into place by HC, especially if they are growing.
Summary MADISON HEIGHTS, MI / ACCESSWIRE / Apr 16, 2014 / Creative Edge Nutrition, Inc. (OTC Pink: FITX) ( FITX ), CEN Biotech announced today that it has engaged Push Point Management Group (PPMG), to provide strategic corporate consulting and capital markets support to CEN Biotech's management team. RXNB possesses proprietary, cutting-edge systems in the field of agriculture, applicable to medical marijuana. In particular, these technologies focus on Current Good Manufacturing Practices (cGMP) manufacturing and growing process of medicinal marijuana. cGMP refers to the Current Good Manufacturing Practice regulations enforced by the US Food and Drug Administration (FDA). cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities, which assures the identity, strength, quality, and purity of drug products.
Good to hear from you, Everywhereman! So how does everyone think tomorrow's conference call will be? You think we'll get some good news or you think it will be standard and vague?
Prohost Observations: We agree with Dr. J. Joseph Kim, Inovio's President and CEO’s statement that the results from the phase 2 study represent a breakthrough in the field of immunotherapies. Indeed, the efficacy results and the T cell data provide evidence that SynCon® immunotherapy technology can activate the immune system to fight chronic infections, pre-cancers and, ultimately, cancers. Mr. Kim believes that the results of Phase 2 trial de-risk Inovio’s product and business development strategy not only regarding VGX-3100, but also the firm’s other pipeline SynCon® active immune therapeutics and vaccine products.
Everywhereman...Where are you? We need your assessment of the current events!
Thanks! I look forward to hearing your full review as always!
Hi Everywherman! I was hoping you could answer a couple of quick questions for me since you seem very competent on Inovio and you also attended the conference. First, what was your take on the reaction the scientific community had regarding the results at the conference? Were they let down by the regression rates or excited about the T-cell response and other factors beyond my scope? Also, I'm your opinion what do you think the chances are that VGX-3100 will go to phase 3? If they do, how long do you think we would have to wait to get word from the FDA that we did get approval for phase 3? That's it! Thanks for your help! I read all your entries and even watch your Dr. Kim interview. Thanks for all your guidance!
Cracity, read my original post. Dilution was the main point. It will come, but it won't be real significant because of the pps post RS if phase 2 results are good. Dilution may potentially benefit stockholders.
We know results will be released in several weeks. It seems the general consensus is that the International Society of DNA Vaccines Conference on July 21-22 in San Diego seems to be the best guess. Makes sense as the RS will happen Friday. This gives them several weeks to stabilize and then rise the PPS. This will be done with the publishing of multiple press releases. They are expected to initiate 2 more clinical studies among other things. The next 2 months should be exciting. Trust me, I believe Dr. Kim had this all strategically mapped out out and timed appropriately. No one could predict the biotech sector would take as large a hit as it did. Having said that, the order of events seems to be aligned perfectly from this point on to benefit the stockholders and PPS with the coming of what we expect to be good news!